Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Yin, Shenyi ^a   Fan, Yu ^a   Zhang, Hanshuo ^a   Zhao, Zhihua ^a   Hao, Yang ^a   Li, Juan ^a   Sun, Changhong ^a   Yang, Junyu ^a   Yang, Zhenjun ^b   Yang, Xiao ^c   Lu, Jian ^a   Xi, Jianzhong Jeff ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 122; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; 5' UNTRANSLATED REGION; MICRORNA; MIRN122 MICRORNA, HUMAN; MIRN122 MICRORNA, MOUSE; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CANCER; CELLS AND CELL COMPONENTS; CYTOGENETICS; GENE EXPRESSION; LIGAND; PHENOTYPE; RODENT;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CANCER SURVIVAL; GENE CONTROL; HUMAN; HUMAN CELL; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LIVER METASTASIS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SPECIES DIFFERENCE; ALLOGRAFT; ANIMAL; BASE PAIRING; CELL LINE; CONSERVED SEQUENCE; DRUG SCREENING; GENETICS; GENOME; LIVER TUMOR; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; SECONDARY; SIGNAL TRANSDUCTION;

MUS; PRIMATES;

5' UNTRANSLATED REGIONS; ALLOGRAFTS; ANIMALS; BASE PAIRING; BASE SEQUENCE; CELL LINE; CONSERVED SEQUENCE; EVOLUTION, MOLECULAR; GENOME; HUMANS; LIVER NEOPLASMS; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961634166     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11012     Document Type: Article

References (52)

1. Hutvágner, G. & Zamore, P. D. A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056-2060 (2002).
2. Wienholds, E. et al. MicroRNA expression in zebrafish embryonic development. Science 309, 310-311 (2005).
3. Flynt, A. S. & Lai, E. C. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat. Rev. Genet. 9, 831-842 (2008).
4. Hobert, O. miRNAs play a tune. Cell 131, 22-24 (2007).
5. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
6. Mendell, J. T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 133, 217-222 (2008).
7. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005).
8. Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005).
9. Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123 (2007).
10. Zhang, H. et al. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat. Commun. 2, 554 (2011).
11. Calin, G. A. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101, 2999-3004 (2004).
12. El-Serag, H. B. Hepatocellular carcinoma. New Engl. J. Med. 365, 1118-1127 (2011).
13. Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27, 1485-1491 (2009).
14. Tsai, W. C. et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49, 1571-1582 (2009).
15. Coulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E. & Thorgeirsson, S. S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526-3536 (2009).
16. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577-1581 (2005).
17. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. New Engl. J. Med. 368, 1685-1694 (2013).
18. Esau, C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87-98 (2006).
19. Krutzfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
20. Hsu, S. H. et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122, 2871-2883 (2012).
21. Blobe, G. C., Schiemann, W. P. & Lodish, H. F. Role of transforming growth factor beta in human disease. New Engl. J. Med. 342, 1350-1358 (2000).
22. Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 13, 788-799 (2013).
23. Thomson, D. W., Bracken, C. P., Szubert, J. M. & Goodall, G. J. On measuring miRNAs after transient transfection of mimics or antisense inhibitors. PLoS ONE 8, e55214 (2013).
24. Sharon, D., Tilgner, H., Grubert, F. & Snyder, M. A single-molecule long-read survey of the human transcriptome. Nat. Biotechnol. 31, 1009-1014 (2013).
25. Derti, A. et al. A quantitative atlas of polyadenylation in five mammals. Genome Res. 22, 1173-1183 (2012).
26. Chi, S. W., Zang, J. B., Mele, A. & Darnell, R. B. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460, 479-486 (2009).
27. Helwak, A., Kudla, G., Dudnakova, T. & Tollervey, D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153, 654-665 (2013).
28. Murray-Zmijewski, F., Slee, E. A. & Lu, X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev. Mol. Cell Biol. 9, 702-712 (2008).
29. Bennett, W. P. et al. Molecular epidemiology of human cancer risk: geneenvironment interactions and p53 mutation spectrum in human lung cancer. J. Pathol. 187, 8-18 (1999).
30. Roessler, S. et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70, 10202-10212 (2010).
31. Roessler, S. et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 142, 957-966 e912 (2012).
32. Wei, R. et al. Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin. Cancer Res. 19, 4780-4791 (2013).
33. Wang, Y. et al. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology 39, 318-324 (2004).
34. Bhattacharyya, S. N., Habermacher, R., Martine, U., Closs, E. I. & Filipowicz, W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 125, 1111-1124 (2006).
35. Girard, M., Jacquemin, E., Munnich, A., Lyonnet, S. & Henrion-Caude, A. miR-122, a paradigm for the role of microRNAs in the liver. J. Hepatol. 48, 648-656 (2008).
36. Beaumont, J. et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-beta1 up-regulation. Clin. Sci. (Lond) 126, 497-506 (2014).
37. Pardali, E. & Ten Dijke, P. TGFbeta signaling and cardiovascular diseases. Int. J. Biol. Sci. 8, 195-213 (2012).
38. Welzel, T. M. et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database. Hepatology 54, 463-471 (2011).
39. Liu, H. & Lu, H. Y. Nonalcoholic fatty liver disease and cardiovascular disease. World J. Gastroenterol. 20, 8407-8415 (2014).
40. Sanches, P. L. et al. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy. J. Clin. Lipidol 8, 265-272 (2014).
41. Jinjuvadia, R., Patel, S. & Liangpunsakul, S. The association between metabolic syndrome and hepatocellular carcinoma systemic review and meta-analysis. J. Clin. Gastroenterol. 48, 172-177 (2014).
42. Massague, J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630 (2012).
43. Dorner, M. et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 474, 208-211 (2011).
44. Du, Y. et al. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell 14, 394-403 (2014).
45. Huang, P. et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 475, 386-389 (2011).
46. Park, C. Y., Choi, Y. S. & McManus, M. T. Analysis of microRNA knockouts in mice. Hum. Mol. Genet. 19, R169-R175 (2010).
47. Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S. & Calin, G. A. MicroRNAs-the micro steering wheel of tumour metastases. Nat. Rev. Cancer 9, 293-302 (2009).
48. Sempere, L. F. et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 5, R13 (2004).
49. Fiedler, J. et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124, 720-730 (2011).
50. Ameres, S. L. & Zamore, P. D. Diversifying microRNA sequence and function. Nat. Rev. Mol. Cell Biol. 14, 475-488 (2013).
51. Erfle, H. et al. Reverse transfection on cell arrays for high content screening microscopy. Nat. Protoc. 2, 392-399 (2007).
52. Yao, B. et al. Quantitative analysis of zeptomole microRNAs based on isothermal ramification amplification. RNA 15, 1787-1794 (2009).